Providing personalized cancer survival rates to patients, families, and physicians.

More than numbers, Courage Health is about the conversation between patients and their doctors about living life on their terms.

Trustworthy 

Courage Health uses the latest research and SEER data from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI).

Courage Health has built 11 proprietary models that provide the most up-to-date estimates of life expectancy.

Personalized

We provide 5 year survival rates for individuals based upon their unique health profile.  Survival rates reflect the outcomes for people with a similar type of cancer and demographic profile.


Information can be shared with physician, family, or other loved ones.

Useful

For patients, knowing survival rates can help to map the journey ahead and prioritize what matters.

For friends and family members, understanding survival rates can help you to support those you love.

For doctors and nurses, we provide the most accurate, current survival rates from NIH's SEER database, a fast and easy interface.

For more information, please contact us at contact@courage.health

Our Team
Stephen Buck, CEO, Co-Founder
  • Advisor, PokitDok, EIR Canaan Partners
  • Prior: Co-Founder, GoodRx, Founder, RxDividends
  • Senior Vice President, Innovation, Physicians’ Desk Reference, VP, McKesson 

Jim Murphy, M.D. M.S., Advisor

  • Oncologist, University of California San Diego, Department of Radiation Medicine and Applied Sciences
  • Dr. Murphy’s clinical specialties include gastrointestinal cancer, palliative radiotherapy as well as health outcomes and epidemiology research.
  • Dr. Murphy has published over 50 journal articles.

Omar Mehmood, CTO, Co-Founder

    • Prior: Principal Engineer, Oration
    • Principal Engineer, Castlight Health
    • M. Eng., Computer Science, Cornell University

Emily Marlow, Ph.D. (ABD), Epidemiologist

    • Ph.D. Epidemiology, UC Davis (expected 2018), M.S. Biostatistics
    • Biostatistician for the Radiation Induced Cancer Study at UC Davis

Advisory Board

Gene Sheih M.D.

    • Radiation Oncologist, South Florida Radiation Oncology/21st Century Radiation Oncology


Andrew Bruggeman M.D.

    • Chief Resident, Radiation Medicine and Applied Science, UCSD 

Komal Patel, Pharm.D.

    • Adjunct Professor, USC School of Pharmacy
    • Former Director of Operations, Med-Plus Pharmacy


Ethan Prater

    • Chairman, Digital Health, Alchemist Accelerator
    • Fmr. SVP Change Healthcare, Fmr. VP, Product Castlight Health

Matt Tindall

    • Fmr. CEO, Omicia
    • Fmr. GM, Consumer Solutions, IMS Health

Adam Schlifke, M.D.

    • Medical Director CEP America

Shoshana Ungerleider, M.D.

    • Internist, hospital medicine at California Pacific Medical Center
    • Founder, End Well